Pandemic-Related Lockdowns Slowing Resumption of Clinical Trials in the UK and U.S.
Data and analytics company GlobalData has found that the number of resumed trials in the UK and the U.S. has increased from 797 in October to 841 in November, which represents the smallest increase since July.
The data firm suggests pandemic-related lockdowns in the UK and some states in the U.S. are slowing the resumption of clinical trials.
GlobalData said 78.6 percent of trials started in mid-November are currently recruiting participants.
Out of the trials that began in November, 8.9 percent of trials have completed recruitment but are ongoing, and 0.7 percent have not yet started to recruit participants. Ongoing recruiting trials decreased from 82.4 percent in October to 78.6 percent in November while completed trials increased from only
6.8 percent in October to 8.1 percent in November.